Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
ApexOnco Front Page
Recent articles
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
The company sticks with EZH2, despite others adding EZH1 inhibition.
Questions continue to swirl as the unit mulls another oncology makeover.
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.